Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients

Eur J Med Res. 2003 May 30;8(5):226-8.

Authors

H B Schneider¹, H Becker

Affiliation

¹ Department of Surgery, Universitity of Göttingen, Robert-Koch-Str.40, D-37075 Göttingen, Germany. hbschneider@chirurgie-goettingen.de

PMID: 12844478

Abstract

The aim of the study is the identification of cancer patients at increased risk for severe toxicity prior to the administration of 5-FU.

Publication types

Review

MeSH terms

Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / adverse effects*
Antimetabolites, Antineoplastic / therapeutic use
Dermatitis / complications
Dermatitis / drug therapy
Diarrhea / chemically induced
Dihydropyrimidine Dehydrogenase Deficiency
Dihydrouracil Dehydrogenase (NADP) / genetics*
Dihydrouracil Dehydrogenase (NADP) / metabolism
Fluorouracil / administration & dosage
Fluorouracil / adverse effects*
Fluorouracil / therapeutic use
Humans
Neoplasms, Glandular and Epithelial / drug therapy*
Neoplasms, Glandular and Epithelial / enzymology*
Risk Factors

Substances

Antimetabolites, Antineoplastic
Dihydrouracil Dehydrogenase (NADP)
Fluorouracil